Compound Profiles

A 15-amino-acid synthetic peptide derived from a gastric protein, widely studied for tissue repair and healing applications.

A long-acting synthetic GHRH analog engineered for extended plasma half-life through albumin binding, widely studied for growth hormone secretagogue effects.

A synthetic tetrapeptide analog of epithalamin studied for telomere elongation, pineal gland regulation, and longevity effects in animal and limited human models.

A naturally occurring copper-binding tripeptide with extensive research in wound healing, collagen synthesis, and skin remodeling.

A second-generation synthetic hexapeptide GHRP with potent GH-releasing activity, studied for GH deficiency diagnosis and body composition research.

The first-generation synthetic GHRP with strong GH-releasing and appetite-stimulating activity, foundational to understanding the ghrelin receptor system.

A potent synthetic hexapeptide GHRP with strong GH-releasing activity and notable cardiac-protective properties in preclinical studies, distinct from other GHRPs through direct cardiac receptor binding.

A synthetic long-acting analog of IGF-1 with an arginine substitution and N-terminal extension that dramatically extends half-life and reduces IGF-binding protein affinity.

A highly selective pentapeptide GHRP with a clean GH release profile and minimal effect on cortisol or prolactin, making it one of the most researched GH secretagogues.

A hypothalamic neuropeptide that directly drives GnRH pulsatility, sitting at the top of the reproductive hormone axis and under active investigation in the menopausal transition.

A cyclic analog of alpha-MSH studied for skin pigmentation, sexual function, and appetite suppression via non-selective melanocortin receptor activation.

A mitochondria-derived peptide encoded in the 12S rRNA mitochondrial genome, studied for insulin sensitization, exercise mimicry, and anti-aging effects.

A hypothalamic nonapeptide with roles in bonding, stress regulation, pain modulation, and cardiovascular protection — with a substantial and growing body of research in post-menopausal women.

A cyclic heptapeptide melanocortin receptor agonist FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women.

A triple GIP/GLP-1/glucagon receptor agonist in Phase III trials showing up to 24% weight loss — potentially the most potent metabolic peptide in clinical development.

A synthetic heptapeptide analog of tuftsin developed in Russia, studied for anxiolytic, nootropic, and immunomodulatory effects with a favorable tolerability profile.

A long-acting GLP-1 receptor agonist with extensive clinical trial data for type 2 diabetes and obesity, among the most-studied peptide therapeutics in the world.

A synthetic heptapeptide analog of ACTH 4-10, approved in Russia for stroke and cognitive impairment, studied for neuroprotection, BDNF upregulation, and nootropic effects.

The first 29 amino acids of native growth hormone-releasing hormone — the shortest GHRH fragment with full biological activity, and the longest-studied GHRH analog in clinical use.

A synthetic analog of Thymosin Beta-4, a naturally occurring peptide involved in actin regulation and tissue repair across multiple organ systems.

A 28-amino-acid thymic peptide with FDA orphan drug status, studied extensively for immune modulation, antiviral activity, and immune reconstitution.

A dual GIP/GLP-1 receptor agonist developed by Eli Lilly showing the largest weight loss results of any peptide therapeutic in clinical trials to date.

A 28-amino-acid neuropeptide with vasodilatory, immunomodulatory, and thermoregulatory properties — studied in inflammatory conditions and, more recently, menopausal vasomotor symptoms.